Contact our team of RNA experts to get started.
Contact usUTR landscape datasets
Identify novel isoforms and map UTRs with End-Seq
Developing RNA-targeting therapies relies on identifying regions uniquely active in disease, while RNA-based treatments depend on untranslated regions (UTRs) that enhance stability and protein production. However, pinpointing active UTRs in specific tissues or disease states is challenging, often limiting the accuracy of machine learning models.
Our 5' and 3' End-Seq assays address this by providing ready to download datasets of experimentally validated UTRs across diverse cell lines and tissues. We also offer custom dataset generation for specific cell types or tissues to support your drug development or research program.
Assay:
End-Seq
Available datasets:
Immortalized cells, tissues, custom
Use cases:
AI model training, drug design
Accelerate AI-Driven Drug Development
Harness the power of clean, high-quality data to advance your AI models. Our End-Seq assays provide precise mapping of active 5’ and 3’ UTRs across a range of immortalized cell lines and human tissues—datasets that are ready for download and optimized for drug discovery.
Need a custom dataset? We can generate exclusive data tailored to your specifications, with flexible sequencing depths to meet your project’s unique needs.
Take the next step in RNA drug development by accessing the data you need today.
Replicable data, actionable data
Each End-Seq dataset is a comprehensive resource, offering everything from raw sequencing data to detailed secondary analyses. The sequencing files and aligned data are prepped for seamless integration into machine learning workflows, while the secondary analyses deliver insights into data quality and the underlying biological system.
Explore the data with interactive reports
To get to actionable insights faster, we have generated interactive reports that reveal quality control metrics and details on where UTRs are located. These reports include tables and interactive plots for data exploration.
Example of our End-Seq report which includes interactive plots and searchable tables.
Reveal disease-specific regions
Different disease states can lead to the expression of different isoforms with specific UTR usage. End-Seq reveals which UTRs are active in a given disease state, providing small molecule developers with lists of druggable regions that are selectively active in the disease and cell type of interest.
A 5’ UTR is more active in cancerous samples and not in healthy samples, making it a potential target for selective regulation in cancer.